INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.910
+0.030 (1.60%)
At close: Dec 5, 2025, 4:00 PM EST
1.880
-0.030 (-1.56%)
After-hours: Dec 5, 2025, 7:50 PM EST
INmune Bio Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for INmune Bio stock ranges from a low of $0.60 to a high of $8.00. The average analyst price target of $4.30 forecasts a 125.13% increase in the stock price over the next year.
Price Target: $4.30 (+125.13%)
Analyst Consensus: Hold
* Price targets were last updated on Jul 2, 2025.
Analyst Ratings
The average analyst rating for INmune Bio stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $30 → $8 | Strong Buy | Maintains | $30 → $8 | +318.85% | Jul 2, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 1, 2025 |
| Scotiabank | Scotiabank | Buy → Sell Downgrades $23 → $0.6 | Buy → Sell | Downgrades | $23 → $0.6 | -68.59% | Jul 1, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +1,470.68% | Feb 13, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $22 → $23 | Buy | Maintains | $22 → $23 | +1,104.19% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
38.25K
from 14.00K
Increased by 173.21%
Revenue Next Year
4.91M
from 38.25K
Increased by 12,733.99%
EPS This Year
-1.77
from -2.11
EPS Next Year
-1.30
from -1.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 52,500 | 15.2M | ||||
| Avg | 38,250 | 4.9M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 275.0% | 39,534.0% | ||||
| Avg | 173.2% | 12,734.0% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.42 | -0.76 | ||||
| Avg | -1.77 | -1.30 | ||||
| Low | -1.90 | -2.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.